286 related articles for article (PubMed ID: 29694244)
1. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
2. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):627-636. PubMed ID: 29694243
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
[TBL] [Abstract][Full Text] [Related]
7. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
9. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
Yan T; Greene M; Chang E; Touya M; Broder MS
J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Lazarus A
Pharmacoeconomics; 2010; 28(9):751-64. PubMed ID: 20623994
[TBL] [Abstract][Full Text] [Related]
14. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
[TBL] [Abstract][Full Text] [Related]
15. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
18. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
